Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06782984 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Drug Response Testing and Repurposing Using Glioblastoma Organoid

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The aim of this observational study, based on a prospectively collected cohort, is to evaluate the prognostic value of patient-derived organoids in predicting responses to conventional and repurposing drugs, including temozolomide, in patients with primary or recurrent glioblastoma. The primary question is whether the patient's response to temozolomide is recapitulated in their corresponding patient-derived glioblastoma organoid (GBO). Patient drug responses are evaluated using survival data, while GBO drug responses are assessed through a drug-response testing platform utilizing cell viability assays. Additionally, this platform is used to explore the potential application of various chemotherapeutic agents.
Trial Details
NCT Number NCT06782984
Lead Sponsor Chungnam National University Hospital
Collaborators: Korea Advanced Institute of Science and Technology, Keimyung University Dongsan Medical Center, Soonchunhyang University Hospital, Dong-A University Hospital, Yeungnam University Hospital
Conditions
(from sponsor)		 Glioblastoma, Organoid
Related terms Glioblastoma
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov